The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
intermediatevalproatehepatotoxicityliver function testsASTALTbipolar disordertherapeutic drug monitoring
A 45-year-old male with bipolar I disorder has been taking divalproex sodium 1000 mg daily for nine months with good mood stabilization. At his routine monitoring visit, laboratory results reveal an AST of 62 U/L (normal: 10-40), ALT of 78 U/L (normal: 7-56), GGT of 55 U/L (normal: 9-48), and total bilirubin of 0.9 mg/dL (normal: 0.1-1.2). His valproic acid level is 85 mcg/mL (therapeutic: 50-125). His albumin is 3.9 g/dL, platelet count is 195,000/microL, and INR is 1.0. He reports no abdominal pain, nausea, jaundice, or fatigue and feels well overall. He denies alcohol use and takes no other hepatotoxic medications. The PMHNP is evaluating the significance of these laboratory findings. Which of the following best represents the appropriate evaluation?
Explanation
Mild transaminase elevations during valproate therapy are common and typically reflect benign enzyme induction rather than progressive hepatotoxicity. The critical evaluation distinction depends on preserved hepatic synthetic function, the absence of symptoms, and elevations remaining below three times the upper limit of normal, with monitoring intervals to assess trajectory.
Key Takeaway
Valproate-related transaminase elevations below three times the upper limit of normal with preserved synthetic function and no symptoms represent benign enzyme induction requiring monitoring rather than medication discontinuation.